Skip to main content
SpringerLink
Log in

Antiallergic Effects of Technologically Processed Antibodies to MHC II

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

The risk of developing anaphylactic reactions to medications introduces additional difficulties for effective pharmacotherapy. Using a model of systemic anaphylaxis in mice, we showed that preventive administration of a preparation containing technologically processed antibodies (TPA) to MHC II induces an anti-anaphylactic effect comparable to that of dexamethasone (when assessing the severity of systemic anaphylaxis 30 and 60 min after challenge injection of the model antigen ovalbumin). The revealed activity may be related to the ability of TPA to MHC II to regulate the antigen presentation system and shift the immune response towards the production of IgG instead of IgE typical of anaphylactic reaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Minciullo PL, Cascio A, David A, Pernice LM, Calapai G, Gangemi S. Anaphylaxis caused by helminths: review of the literature. Eur. Rev. Med. Pharmacol. Sci. 2012;16(11):1513-1518.

    CAS  PubMed  Google Scholar 

  2. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J. Allergy Clin. Immunol. Pract. 2017;5(5):1169-1178. doi: https://doi.org/10.1016/j.jaip.2017.06.031

    Article  PubMed  PubMed Central  Google Scholar 

  3. Maker JH, Stroup CM, Huang V, James SF. Antibiotic hypersensitivity mechanisms. Pharmacy (Basel). 2019;7(3):122. doi: https://doi.org/10.3390/pharmacy7030122

    Article  PubMed  PubMed Central  Google Scholar 

  4. Teymurazov MG, Petrova NV, Karelina EA, Ganina KK, Tarasov SA, Epstein OI. Nonclinical study of the new immunotropic drug effectiveness in salmonella infection treatment. Byull. Sib. Med. 2021;20(2):95-101. Russian. doi: https://doi.org/10.20538/1682-0363-2021-2-95-101

  5. Emelianova AG, Petrova NV, Fremez C, Fontanié M, Tarasov SA, Epstein OI. Therapeutic potential of highly diluted antibodies in antibiotic-resistant infection. Eur. J. Pharm. Sci. 2022;173:106161. doi: https://doi.org/10.1016/j.ejps.2022.106161

    Article  CAS  PubMed  Google Scholar 

  6. Tarasov SA, Gorbunov EA, Don ES, Emelyanova AG, Kovalchuk AL, Yanamala N, Schleker ASS, Klein-Seetharaman J, Groenestein R, Tafani JP, van der Meide P, Epstein OI. Insights into the mechanism of action of highly diluted biologics. J. Immunol. 2020;205(5):1345-1354. doi: https://doi.org/10.4049/jimmunol.2000098

    Article  CAS  PubMed  Google Scholar 

  7. Penkov N. Antibodies processed using high dilution technology distantly change structural properties of IFNγ aqueous solution. Pharmaceutics. 2021;13(11):1864. doi: https://doi.org/10.3390/pharmaceutics13111864

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Epshtein OI, Shtark MB, Kolyadko TS. Method of treating a pathological syndrome and a pharmaceutical agent. Patent US-7815904-B2. Oct. 19, 2010.

  9. Bunkin NF, Shkirin AV, Ninham BW, Chirikov SN, Chaikov LL, Penkov NV, Kozlov VA, Gudkov SV. Shaking-induced aggregation and flotation in immunoglobulin dispersions: differences between water and water-ethanol mixtures. ACS Omega. 2020;5(24):14 689-14 701. doi: https://doi.org/10.1021/acsomega.0c01444

  10. Rupa P, Mine Y. Engineered recombinant ovomucoid third domain can desensitize Balb/c mice of egg allergy. Allergy. 2006;61(7):836-842. doi: https://doi.org/10.1111/j.1398-9995.2006.01143.x

    Article  CAS  PubMed  Google Scholar 

  11. Martínez-Gómez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kündig TM. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 2009;64(1):172-178. doi: https://doi.org/10.1111/j.1398-9995.2008.01812.x

    Article  CAS  PubMed  Google Scholar 

  12. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 2004;113(6):1025-1034; quiz 1035. doi: https://doi.org/10.1016/j.jaci.2004.03.024

  13. Ozdemir C, Akdis M, Akdis CA. T-cell response to allergens. Chem. Immunol. Allergy. 2010;95:22-44. doi: https://doi.org/10.1159/000315936

    Article  CAS  PubMed  Google Scholar 

  14. Khamitov RF, Nikiforov VV, Zaytsev AA, Tragira IN. Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection. Ter. Arkhiv. 2022;94(1):83-93. Russian. doi: https://doi.org/10.26442/00403660.2022.01. 201345

Download references

Author information

Authors and Affiliations

  1. Research Institute of General Pathology and Pathophysiology, Moscow, Russia

    N. V. Petrova & S. A. Tarasov

  2. LLC “MATERIA MEDICA HOLDING”, Moscow, Russia

    N. V. Petrova & S. A. Tarasov

  3. National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia

    A. A. Galkina, A. S. Poroshina, M. S. Sundukova & V. V. Smirnov

Authors
  1. N. V. Petrova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Tarasov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Galkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. S. Poroshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. S. Sundukova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. V. Smirnov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. V. Petrova.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 175, No. 6, pp. 763-766, June, 2023

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrova, N.V., Tarasov, S.A., Galkina, A.A. et al. Antiallergic Effects of Technologically Processed Antibodies to MHC II. Bull Exp Biol Med 175, 801–803 (2023). https://doi.org/10.1007/s10517-023-05950-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-023-05950-8

Keywords

Search

Navigation